MétaCan
Menu
Back to cohort
Record W2559197523 · doi:10.1093/neuonc/now212.070

ATIM-05. COMPLEMENTARY CLINICAL AND ANCILLARY DATA FROM 123 PATIENTS WITH RECURRENT HIGH GRADE GLIOMA FROM THREE PHASE 1 TRIALS OF TOCA 511 AND TOCA FC: UPDATE AND JUSTIFICATION FOR A PHASE 2/3 TRIAL

2016· article· en· W2559197523 on OpenAlexaff
Manish K. Aghi, Michael A. Vogelbaum, Steven N. Kalkanis, Daniela A. Bota, Bob S. Carter, Clark Chen, Bradley Elder, Johnathan A. Engh, Samuel Goldlust, George Kaptain, Santosh Kesari, Joseph Landolfi, Linda M. Liau, Tom Mikkelsen, David Piccioni, Jana Portnow, Samuel Singer, Tobias Walbert, Harry E. Gruber, Carlos E. Ibañez, Douglas J. Jolly, Leah Mitchell, Derek Ostertag, Jolene Shorr, Liqiang Yang, Asha Das, Timothy F. Cloughesy

Bibliographic record

VenueNeuro-Oncology · 2016
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicVirus-based gene therapy research
Canadian institutionsOntario Brain Institute
Fundersnot available
KeywordsImmune systemTumor microenvironmentGliomaCancer researchMedicineImmunology

Abstract

fetched live from OpenAlex

Toca 511 (vocimagene amiretrorepvec) is an investigational, conditionally lytic, retroviral replicating vector. The vector infects human cells with selectivity for cancer cells because genome integration is dependent on cell division and viral replication is inhibited by innate and adaptive immune responses, defective in malignant tissues. Toca 511 spreads through cancer cells and stably delivers the gene for an optimized yeast cytosine deaminase that converts courses of the prodrug Toca FC (an investigational, extended-release version of 5-fluorocytosine) into 5-fluorouracil (5-FU). The 5-FU directly kills cancer cells likely leading to activation of antigen presenting cells in the tumor microenvironment. 5-FU can also diffuse into nearby immunosuppressive myeloid cells and kill them, leading to further activation of the immune system against the tumor by removing an important inflammatory brake. The safety, viral kinetics, immune response, and preliminary efficacy of Toca 511 and Toca FC have been investigated since 2010 in three, open-label, ascending dose, Phase 1 studies of 123 patients with recurrent high grade glioma (rHGG), each evaluating different methods of Toca 511 administration (intratumoral injection, injection into the cavity wall following resection, and intravenous injection followed by resection and injection into resection cavity wall) followed by multiple courses of oral Toca FC. Results to date include good tolerability; no persistent viremia; successful gene transduction within resected tumors; and median overall survival with stereotactic biopsy needle, resection cavity wall, and intravenous/cavity wall vector injection ranging from 12.1–13.6 months. Analysis of pretreatment resected tumor samples for mRNA expression patterns showed a survival-related signature that otherwise does not correlate with survival in publically available databases. Preliminary data from these studies supported initiation of a randomized, Phase 2/3 study in patients with rHGG (NCT02414165) in 2015. Updated and pooled safety data, immune response findings, and updated efficacy data for the Phase 1 studies will be presented.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.003
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Non-randomized trial · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.010
Threshold uncertainty score0.033

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0030.003
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0020.002
Bibliometrics0.0010.001
Science and technology studies0.0010.000
Scholarly communication0.0010.001
Open science0.0010.000
Research integrity0.0010.002
Insufficient payload (model declined to judge)0.0100.003

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.175
GPT teacher head0.449
Teacher spread0.273 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNon-randomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2016
Admission routes1
Has abstractyes

Explore more

Same venueNeuro-OncologySame topicVirus-based gene therapy researchFrench-language works237,207